Page last updated: 2024-10-15

kutkin

Description

kutkin: alcoholic extract of the root and rrhizome of Picrorhiza kurrooa; has heptatoprotective activity; contains picroside I, kutkoside, and a small amount of other minor glycosides of P. kurrooa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131750182
MeSH IDM0160792

Synonyms (4)

Synonym
kutkin
picroliv
12708-05-3
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(e)-3-phenylprop-2-enoyl]oxybenzoate;dihydrate

Toxicity

ExcerptReference
"Cadmium (Cd), an industrial and environmental pollutant, is toxic to several tissues, most notably causing hepatotoxicity on acute administration and nephrotoxicity following chronic exposure."( Therapeutic efficacy of Picroliv in chronic cadmium toxicity.
Khandelwal, S; Yadav, N, 2009
)
" The histopathological examination on toxic models revealed centrizonal necrosis and fatty changes."( Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice.
Girish, C; Jayanthi, S; Koner, BC; Pradhan, SC; Rajesh, B; Ramachandra Rao, K, 2009
)

Pharmacokinetics

ExcerptReference
" Therefore, this study was designed to check metabolic (in vitro and in vivo) profile along with pharmacokinetic profile of picroside I and II."( In vitro - In vivo metabolism and pharmacokinetics of picroside I and II using LC-ESI-MS method.
Anandjiwala, S; Nivsarkar, M; Padh, H; Upadhyay, D, 2016
)

Compound-Compound Interactions

ExcerptReference
"The effect of Picroliv treatment on the carcinogenic response and, hepatic and renal antioxidant enzymes of rats administered with 1,2-dimethylhydrazine hydrochloride (DMH) was studied in male Sprague-Dawley rats."( Modulation of carcinogenic response and antioxidant enzymes of rats administered with 1,2-dimethylhydrazine by Picroliv.
Kuttan, R; Rajeshkumar, NV, 2003
)
" We therefore examined the possibility of minimizing these effects by applying miltefosine in lower doses in combination with picrloviv, an immunomodulator against Leishmania donovani in hamsters (Mesocricetus auratus)."( Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.
Gupta, S; Ramesh, SC; Srivastava, VM, 2005
)
" To combat this situation, leishmanicidal efficacy of already marketed standard antifungal drug, fluconazole under the approach of "therapeutic switching" in combination with standard antileishmanial drug, miltefosine, and a potent immunomodulator agent, picroliv, were evaluated in hamsters infected with Leishmania donovani."( Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
Gupta, S; Sane, SA; Shakya, N, 2011
)

Bioavailability

ExcerptReference
" However, poor bioavailability and temperature and light sensitivity can reduce the efficacy of drugs like curcumin."( Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin.
Girish, C; Pradhan, SC, 2008
)
"05) in oral bioavailability of picrosides I and II from different preparations."( Comparative pharmacokinetic profiles of picrosides I and II from kutkin, Picrorhiza kurroa extract and its formulation in rats.
Anandjiwala, S; Dash, RP; Nivsarkar, M; Upadhyay, D, 2013
)
" Previously, we have reported that oral bioavailability of picroside I and II is low."( In vitro - In vivo metabolism and pharmacokinetics of picroside I and II using LC-ESI-MS method.
Anandjiwala, S; Nivsarkar, M; Padh, H; Upadhyay, D, 2016
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.45)18.7374
1990's31 (44.93)18.2507
2000's26 (37.68)29.6817
2010's9 (13.04)24.3611
2020's2 (2.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.39%)5.53%
Reviews2 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]